Clinical data suggest that the use of adjuvant tamoxifen citrate (Nolvadex) for a minimum of 5 years, and possibly indefinitely, will result in maximal antitumor benefit. There is concern that long-term tamoxifen maintenance therapy may result in the induction of drug resistance. This article reviews the potential molecular mechanisms of resistance to tamoxifen and explores the possibility of tamoxifen-stimulated tumor growth.
(Arch Surg. 1993;128:1187-1191)
Morrow M, Jordan VC. Molecular Mechanisms of Resistance to Tamoxifen Therapy in Breast Cancer. Arch Surg. 1993;128(11):1187-1191. doi:10.1001/archsurg.1993.01420230015002